newsfilter
← Latest News
GlobeNewswire·

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical